Models of cardiac hypertrophy and transition to heart failure

Drug Discovery Today: Disease Models

Volumn 4, Issue 4, 2007, Pages 197-206

  Berry, Jeff M ^b   Naseem, R Haris ^b   Rothermel, Beverly A ^b   Hill, Joseph A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ARGININE; BETA 1 ADRENERGIC RECEPTOR; CALCINEURIN; CALCIUM ION; GLYCINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOPRENALINE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN BETA; NEUROHORMONE; PHENYLEPHRINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE (CALCIUM,CALMODULIN) II; PROTEIN KINASE B; PROTEIN KINASE D; RENIN; THYROID HORMONE; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SUBSTITUTION; AORTA STENOSIS; CELL CULTURE; CELL SIZE; COMPUTER MODEL; CORONARY ARTERY LIGATION; CYTOKINE PRODUCTION; DAHL SALT SENSITIVE RAT; DISEASE COURSE; DISEASE MODEL; DOG; DRUG TARGETING; EXTRACELLULAR MATRIX; FIBROBLAST; GENE MUTATION; GENE OVEREXPRESSION; GENETIC MODEL; HEART EJECTION FRACTION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WORK; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MECHANICS; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PROCESS MODEL; REVIEW; SHEEP; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HEART FAILURE;

EID: 46749105977     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2007.06.003     Document Type: Review

References (69)

1. Rosamond W., et al. Heart Disease and Stroke Statistics-2007 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
2. Heineke J., and Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev. Mol. Cell Biol. 7 (2006) 589-600
3. Levy D., et al. The progression from hypertension to congestive heart failure. Jama 275 (1996) 1557-1562
4. Frey N., et al. Hypertrophy of the heart: a new therapeutic target?. Circulation 109 (2004) 1580-1589
5. Berenji K., et al. Does load-induced ventricular hypertrophy progress to systolic heart failure?. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H8-H16
6. Sambrano G.R., et al. Navigating the signalling network in mouse cardiac myocytes. Nature 420 (2002) 712-714
7. Sucharov C.C., et al. A beta1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H1299-H1308
8. Hu C.M., et al. Heme oxygenase-1 inhibits angiotensin II-induced cardiac hypertrophy in vitro and in vivo. Circulation 110 (2004) 309-316
9. Jeong D., et al. PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility. Circ. Res. 99 (2006) 307-314
10. Jaffre F., et al. Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. Circulation 110 (2004) 969-974
11. Planavila A., et al. Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J. Biol. Chem. 280 (2005) 17464-17471
12. Zheng B., et al. hhLIM protein is involved in cardiac hypertrophy. Biochim. Biophys. Acta 1690 (2004) 1-10
13. Edwards J.G. In vivo beta-adrenergic activation of atrial natriuretic factor (ANF) reporter expression. Mol. Cell Biochem. 292 (2006) 119-129
14. Nelson T.J., et al. SRF-dependent gene expression in isolated cardiomyocytes: regulation of genes involved in cardiac hypertrophy. J. Mol. Cell Cardiol. 39 (2005) 479-489
15. Rockman H.A., et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 8277-8281
16. Rothermel B.A., et al. Differential activation of stress-response signaling in load-induced cardiac hypertrophy and failure. Physiol. Genom. 23 (2005) 18-27
17. Depre C., et al. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114 (2006) 1821-1828
18. Moorjani N., et al. Activation of apoptotic caspase cascade during the transition to pressure overload-induced heart failure. J. Am. Coll. Cardiol. 48 (2006) 1451-1458
19. Balasubramanian S., et al. Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium is accompanied by changes in specific E3 ligases. J. Mol. Cell Cardiol. 41 (2006) 669-679
20. Page I.H. A method for producing persistent hypertension by cellophane. Science 89 (1939) 273-274
21. Munagala V.K., et al. Ventricular structure and function in aged dogs with renal hypertension: a model of experimental diastolic heart failure. Circulation 111 (2005) 1128-1135
22. Rysa J., et al. Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. Hypertension 45 (2005) 927-933
23. Iwanaga Y., et al. Excessive activation of matrix metalloproteinases coincides with left ventricular remodeling during transition from hypertrophy to heart failure in hypertensive rats. J. Am. Coll. Cardiol. 39 (2002) 1384-1391
24. Hankes G.H., et al. Beta1-adrenoceptor blockade mitigates excessive norepinephrine release into cardiac interstitium in mitral regurgitation in dog. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H147-H151
25. Cantor E.J., et al. A comparative serial echocardiographic analysis of cardiac structure and function in rats subjected to pressure or volume overload. J. Mol. Cell Cardiol. 38 (2005) 777-786
26. 2+ leak in heart failure. Circ. Res. 97 (2005) 1314-1322
27. Akar F.G., et al. Molecular mechanisms underlying K+ current downregulation in canine tachycardia-induced heart failure. Am. J. Physiol. Heart Circ. Physiol. 288 (2005) H2887-H2896
28. Poelzing S., and Rosenbaum D.S. Altered connexin43 expression produces arrhythmia substrate in heart failure. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H1762-H1770
29. Wilkoff B.L., et al. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA 288 (2002) 3115-3123
30. Sharma A.D., et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm 2 (2005) 830-834
31. Most P., et al. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 114 (2006) 1258-1268
32. Curcio A., et al. Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H1754-H1760
33. Port J.D., and Bristow M.R. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J. Mol. Cell Cardiol. 33 (2001) 887-905
34. Freund C., et al. Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation 111 (2005) 2319-2325
35. Wilkins B.J., et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94 (2004) 110-118
36. Degens H., et al. Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H108-H115
37. Milliken M.C., et al. Left ventricular mass as determined by magnetic resonance imaging in male endurance athletes. Am. J. Cardiol. 62 (1988) 301-305
38. Fagard R. Athlete's heart. Heart 89 (2003) 1455-1461
39. Shiojima I., and Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev. 20 (2006) 3347-3365
40. DeBosch B., et al. Akt1 is required for physiological cardiac growth. Circulation 113 (2006) 2097-2104
41. De Bono J.P., et al. Novel quantitative phenotypes of exercise training in mouse models. Am. J. Physiol. Regul. Integr. Comp. Physiol. 290 (2006) R926-R934
42. Konhilas J.P., et al. Sex modifies exercise and cardiac adaptation in mice. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H2768-H2776
43. Yutzey K.E., and Robbins J. Principles of genetic murine models for cardiac disease. Circulation 115 (2007) 792-799
44. Seeland U., et al. Interstitial remodeling in beta1-adrenergic receptor transgenic mice. Basic Res. Cardiol. 102 (2007) 183-193
45. Zhai P., et al. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin II-mediated cardiac hypertrophy. Circ. Res. 99 (2006) 528-536
46. Molkentin J.D., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93 (1998) 215-228
47. Zhang T., et al. The deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated cardiomyopathy and heart failure. Circ. Res. 92 (2003) 912-919
48. Nicol R.L., et al. Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 20 (2001) 2757-2767
49. Harrison B.C., et al. Regulation of cardiac stress signaling by protein kinase d1. Mol. Cell Biol. 26 (2006) 3875-3888
50. Ahmad F., et al. The genetic basis for cardiac remodeling. Annu. Rev. Genomics Hum. Genet 6 (2005) 185-216
51. Wolf C.M., et al. Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18123-18128
52. Song Q., et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J. Clin. Invest 111 (2003) 859-867
53. Sadoshima J., and Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu. Rev. Physiol. 59 (1997) 551-571
54. Suga H., et al. Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circ. Res. 32 (1973) 314-322
55. Vasan R.S., et al. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N. Engl. J. Med. 336 (1997) 1350-1355
56. Vasan R.S., et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J. Am. Coll. Cardiol. 33 (1999) 1948-1955
57. Wang T.J., et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108 (2003) 977-982
58. Sadoshima J., et al. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J. Clin. Invest. 110 (2002) 271-279
59. Okumura S., et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 9986-9990
60. Zile M.R., et al. Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N. Engl. J. Med. 350 (2004) 1953-1959
61. Merx M.W., et al. Myocardial stiffness, cardiac remodeling and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J. Am. Soc. Nephrol. 16 (2005) 3357-3364
62. Vega R.B., et al. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell Biol. 24 (2004) 8374-8385
63. Brown R.D., et al. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev. Pharmacol. Toxicol. 45 (2005) 657-687
64. Bruckner B.A., et al. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J. Heart Lung Transplant 20 (2001) 457-464
65. Luo C.H., and Rudy Y. A dynamic-model of the cardiac ventricular action-potential .1. Simulations of ionic currents and concentration changes. Circ. Res. 74 (1994) 1071-1096
66. Luo C.H., and Rudy Y. A dynamic-model of the cardiac ventricular action-potential. 2. After depolarizations, triggered activity and potentiation. Circ. Res. 74 (1994) 1097-1113
67. Zou R., et al. Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H1002-H1012
68. Wiegerinck R.F., et al. Larger cell size in rabbits with heart failure increases myocardial conduction velocity and QRS duration. Circulation 113 (2006) 806-813
69. Hill J.A., et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 101 (2000) 2863-2869